Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF® (+27%) and APONVIE® (+50%)Q1 2026 total net ...
Heron Therapeutics (NASDAQ:HRTX) said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving ...
Q1 2026 Management View “Total net sales of $34.7 million in Q1,” including “ZYNRELEF at $10.2 million, APONVIE at $3.4 million; on the oncology side, $21.1 million combined: CINVANTI at $20.5 million ...
Heron Therapeutics maintained its full-year outlook as growth in its Acute Care franchise helped offset ongoing weakness in oncology products during the first quarter. Key Investor TakeawaysHeron ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results